<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><description>聚焦医药投研</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 10 May 2021 17:21:55 +0800</pubDate><image><url>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</url><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>从销售数据看细胞与基因治疗的竞争格局</title><link>https://mp.weixin.qq.com/s/HIwsVnyg-r-1qhZkhhVc6w</link><description></description><content:encoded><![CDATA[从销售数据看细胞与基因治疗的竞争格局]]></content:encoded><pubDate>Mon, 10 May 2021 16:58:26 +0800</pubDate></item><item><title>靶向IL-4Rα，潜在百亿美元市场的重磅药物</title><link>https://mp.weixin.qq.com/s/BFjPOMV9FnjEnf3ZLVRMZA</link><description></description><content:encoded><![CDATA[靶向IL-4Rα，潜在百亿美元市场的重磅药物]]></content:encoded><pubDate>Fri, 07 May 2021 14:25:35 +0800</pubDate></item><item><title>胃癌一线疗法迎来新格局</title><link>https://mp.weixin.qq.com/s/gnsbqH9yhOgO06vANez7Xw</link><description></description><content:encoded><![CDATA[胃癌一线疗法迎来新格局]]></content:encoded><pubDate>Thu, 06 May 2021 15:15:54 +0800</pubDate></item><item><title>开发CAR-T治疗实体瘤的科济药业</title><link>https://mp.weixin.qq.com/s/Ij1ns3Lfrg9VrKslBdAcDA</link><description></description><content:encoded><![CDATA[开发CAR-T治疗实体瘤的科济药业]]></content:encoded><pubDate>Mon, 26 Apr 2021 16:19:23 +0800</pubDate></item><item><title>HER2靶点-胃癌进入精准治疗时代再出发</title><link>https://mp.weixin.qq.com/s/oepQm4OULkBb0FmwBt5kEQ</link><description></description><content:encoded><![CDATA[HER2靶点-胃癌进入精准治疗时代再出发]]></content:encoded><pubDate>Sun, 25 Apr 2021 12:41:56 +0800</pubDate></item><item><title>人工智能（AI）给药物研发带来了哪些成果</title><link>https://mp.weixin.qq.com/s/XS4MJwxr_Qxi6Hk1OCFuyQ</link><description></description><content:encoded><![CDATA[人工智能（AI）给药物研发带来了哪些成果]]></content:encoded><pubDate>Fri, 23 Apr 2021 09:14:34 +0800</pubDate></item><item><title>中国biotech会成为MNC么？</title><link>https://mp.weixin.qq.com/s/XYcNUsgPt5vUNZJX-ccDlQ</link><description></description><content:encoded><![CDATA[中国biotech会成为MNC么？]]></content:encoded><pubDate>Tue, 20 Apr 2021 12:02:58 +0800</pubDate></item><item><title>Claudin18.2靶点引发国内创新药企内卷大战</title><link>https://mp.weixin.qq.com/s/z7UwFAXS-3Dw5Rk-I1rOsw</link><description></description><content:encoded><![CDATA[Claudin18.2靶点引发国内创新药企内卷大战]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:12:25 +0800</pubDate></item><item><title>mRNA疫苗好，国内企业递送技术如何？</title><link>https://mp.weixin.qq.com/s/rnqK4LN-qjVT_9F0a2vZSQ</link><description></description><content:encoded><![CDATA[mRNA疫苗好，国内企业递送技术如何？]]></content:encoded><pubDate>Wed, 14 Apr 2021 11:06:34 +0800</pubDate></item><item><title>Achilles公司开发TIL+新生抗原治疗实体瘤，市值6亿美元</title><link>https://mp.weixin.qq.com/s/ItWKnSEcqGGj6ENcYne2sA</link><description></description><content:encoded><![CDATA[Achilles公司开发TIL+新生抗原治疗实体瘤，市值6亿美元]]></content:encoded><pubDate>Mon, 12 Apr 2021 18:36:44 +0800</pubDate></item></channel></rss>